Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Syndax Pharma (SNDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 158,728
  • Shares Outstanding, K 24,836
  • Annual Sales, $ 2,110 K
  • Annual Income, $ -60,800 K
  • 36-Month Beta 2.38
  • Price/Sales 67.60
  • Price/Cash Flow N/A
  • Price/Book 2.20

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.68
  • Number of Estimates 4
  • High Estimate -0.63
  • Low Estimate -0.74
  • Prior Year -0.80
  • Growth Rate Est. (year over year) +15.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.12 +24.80%
on 01/30/19
6.60 -3.18%
on 01/16/19
+0.05 (+0.79%)
since 01/15/19
3-Month
3.39 +88.50%
on 12/26/18
6.68 -4.34%
on 01/11/19
+1.47 (+29.88%)
since 11/15/18
52-Week
3.39 +88.50%
on 12/26/18
15.20 -57.96%
on 04/03/18
-3.53 (-35.58%)
since 02/15/18

Most Recent Stories

More News
New Research: Key Drivers of Growth for Cronos Group, Spectrum Brands, Black Hills, Entercom Communications, CSS Industries, and Syndax Pharmaceuticals -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Cronos Group Inc. (NASDAQ:CRON),...

CRON : 21.29 (+2.26%)
CSS : 7.51 (-0.27%)
SPB : 54.25 (+1.69%)
SNDX : 6.39 (+5.62%)
BKH : 69.64 (+0.16%)
ETM : 7.35 (-0.14%)
Syndax Highlights 2019 Clinical and Corporate Outlook

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today provided a 2019 clinical...

SNDX : 6.39 (+5.62%)
Investor Expectations to Drive Momentum within CommScope Holding, AMC Networks, Henry Schein, Lindblad Expeditions, Apple Hospitality REIT, and Syndax Pharmaceuticals -- Discovering Underlying Factors of Influence

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of CommScope Holding Company,...

LIND : 13.08 (+3.97%)
COMM : 22.68 (+2.21%)
HSIC : 62.39 (+0.03%)
APLE : 16.36 (+1.43%)
SNDX : 6.39 (+5.62%)
AMCX : 64.46 (+2.25%)
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Lags Revenue Estimates

Syndax (SNDX) delivered earnings and revenue surprises of 10.53% and -0.26%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

SNDX : 6.39 (+5.62%)
Syndax Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Clinical and Business Update

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial...

SNDX : 6.39 (+5.62%)
Syndax Pharmaceuticals Announces Presentations at the 60th American Society of Hematology Annual Meeting

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the...

SNDX : 6.39 (+5.62%)
Syndax to Announce Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 5, 2018

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it...

SNDX : 6.39 (+5.62%)
Syndax to Host Conference Call to Provide Update on the Phase 3 Breast Cancer Trial (E2112) and to Announce its Registration Trial of Entinostat with Keytruda in PD-(L)1 Refractory Non-Small Cell Lung Cancer

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced it will provide...

SNDX : 6.39 (+5.62%)
Report: Exploring Fundamental Drivers Behind Syndax Pharmaceuticals, Arconic, Del Taco Restaurants, Aerohive Networks, KalVista Pharmaceuticals, and Adtalem Global Education -- New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Syndax Pharmaceuticals,...

HIVE : 4.43 (+1.84%)
KALV : 21.35 (+8.93%)
ARNC : 17.55 (+0.34%)
SNDX : 6.39 (+5.62%)
TACO : 10.20 (unch)
ATGE : 48.47 (+0.66%)
Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab)

Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced updated...

MRK : 79.81 (+1.10%)
SNDX : 6.39 (+5.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

See More Share

Trade SNDX with:

Business Summary

Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253...

See More

Key Turning Points

2nd Resistance Point 6.66
1st Resistance Point 6.53
Last Price 6.39
1st Support Level 6.15
2nd Support Level 5.90

See More

52-Week High 15.20
Fibonacci 61.8% 10.69
Fibonacci 50% 9.30
Fibonacci 38.2% 7.90
Last Price 6.39
52-Week Low 3.39

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar